Shelter Pharma Limited (BOM:543963)
India · Delayed Price · Currency is INR 42.89
-0.13 (-0.30%)
At close: Feb 12, 2026
Shelter Pharma Income Statement
Financials in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 | Mar '21 Mar 31, 2021 |
Other Revenue | -0 | -0 | -0 | - | 0 | - |
| 598.96 | 506.6 | 400.23 | 361.53 | 300.56 | 224.83 | |
Revenue Growth (YoY) | 33.79% | 26.58% | 10.71% | 20.29% | 33.68% | -25.22% |
Cost of Revenue | 442.07 | 370.31 | 289.26 | 262.66 | 259.05 | 211.93 |
Gross Profit | 156.89 | 136.29 | 110.97 | 98.87 | 41.51 | 12.91 |
Selling, General & Admin | 19.07 | 16.77 | 9.08 | 6.28 | 5.41 | 5.45 |
Other Operating Expenses | 20.46 | 15.81 | 11.1 | 8.27 | 5.73 | 5.63 |
Operating Expenses | 46.12 | 38.26 | 25.63 | 19.2 | 15.83 | 15.24 |
Operating Income | 110.77 | 98.03 | 85.34 | 79.67 | 25.68 | -2.34 |
Interest Expense | - | -0.01 | -2.11 | -0.06 | -0.63 | -0.14 |
Interest & Investment Income | 0.06 | - | - | - | 0 | 0.02 |
Currency Exchange Gain (Loss) | -0.03 | -0.03 | 0.02 | 0.02 | 0 | 0.05 |
Other Non Operating Income (Expenses) | -1.19 | -1.22 | -0.43 | -0.81 | 0 | 0.03 |
EBT Excluding Unusual Items | 109.61 | 96.77 | 82.83 | 78.82 | 25.06 | -2.37 |
Other Unusual Items | - | - | - | -9 | - | - |
Pretax Income | 109.61 | 96.77 | 82.83 | 69.82 | 25.06 | -2.37 |
Income Tax Expense | 27.59 | 24.4 | 20.82 | 17.76 | 6.69 | 0.01 |
Net Income | 82.02 | 72.37 | 62 | 52.06 | 18.37 | -2.39 |
Net Income to Common | 82.02 | 72.37 | 62 | 52.06 | 18.37 | -2.39 |
Net Income Growth | 23.61% | 16.73% | 19.10% | 183.39% | - | - |
Shares Outstanding (Basic) | 12 | 12 | 12 | 8 | 8 | 8 |
Shares Outstanding (Diluted) | 16 | 12 | 12 | 8 | 8 | 8 |
Shares Change (YoY) | 38.19% | - | 49.28% | - | 2.90% | 3.60% |
EPS (Basic) | 7.09 | 6.26 | 5.36 | 6.72 | 2.37 | -0.32 |
EPS (Diluted) | 5.14 | 6.26 | 5.36 | 6.72 | 2.37 | -0.32 |
EPS Growth | -10.51% | 16.79% | -20.24% | 183.28% | - | - |
Free Cash Flow | -12.8 | 28.32 | -28.14 | -9.68 | -0.88 | -2.92 |
Free Cash Flow Per Share | -0.80 | 2.45 | -2.43 | -1.25 | -0.11 | -0.39 |
Dividend Per Share | - | 0.350 | 0.330 | - | - | - |
Dividend Growth | - | 6.06% | - | - | - | - |
Gross Margin | 26.19% | 26.90% | 27.73% | 27.35% | 13.81% | 5.74% |
Operating Margin | 18.49% | 19.35% | 21.32% | 22.04% | 8.54% | -1.04% |
Profit Margin | 13.69% | 14.29% | 15.49% | 14.40% | 6.11% | -1.06% |
Free Cash Flow Margin | -2.14% | 5.59% | -7.03% | -2.68% | -0.29% | -1.30% |
EBITDA | 114.34 | 100.71 | 87.8 | 81.31 | 27.37 | -1.17 |
EBITDA Margin | 19.09% | 19.88% | 21.94% | 22.49% | 9.11% | -0.52% |
D&A For EBITDA | 3.58 | 2.68 | 2.46 | 1.64 | 1.69 | 1.16 |
EBIT | 110.77 | 98.03 | 85.34 | 79.67 | 25.68 | -2.34 |
EBIT Margin | 18.49% | 19.35% | 21.32% | 22.04% | 8.54% | -1.04% |
Effective Tax Rate | 25.17% | 25.21% | 25.14% | 25.44% | 26.68% | - |
Revenue as Reported | 599.04 | 506.66 | 400.27 | 361.55 | 300.58 | 224.89 |
Advertising Expenses | - | 0.59 | 0.42 | 0.46 | 0.36 | 0.33 |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.